Navigation Links
Microarray provides 3 genomic guides to breast cancer treatment decisions
Date:9/7/2007

HOUSTON - Three genomic tests separately predict the likelihood that a patient's breast cancer will reoccur after surgery without additional treatment, and the cancer's vulnerability to chemotherapy or hormone therapy, researchers at The University of Texas M. D. Anderson Cancer Center report at the first American Society of Clinical Oncology ASCO Breast Cancer Symposium Sept. 7-8 in San Francisco.

Each predictor - of prognosis, of sensitivity to chemotherapy and sensitivity to hormone therapy - is independent of the others, providing unique information to physicians and patients considering treatment options, says W. Fraser Symmans, M.D., professor in M. D. Anderson's Department of Pathology.

"Existing genomic tests for breast cancer provide information about future risk in general, but not the likely benefit of each treatment option separate from a patient's overall prognosis if no treatment followed surgery. It is important to independently assess these three variables," Symmans says.

Symmans and Lajos Pusztai, M.D., Ph.D., associate professor in M. D. Anderson's Department of Breast Medical Oncology will present two research updates on the genomic predictors, which can be reported from a single microarray analysis of a needle biopsy of a patient's breast cancer.

Symmans will present results from two studies involving 960 patients validating a 200-gene index that predicts a patient's response to hormone-suppressing therapy. About 70 percent of breast cancers express the estrogen receptor (ER), indicating that their growth is fueled to some extent by the female hormone estrogen. Anti-estrogen therapies such as tamoxifen only benefit about half of these patients. The challenge is to predict exactly who will be helped and who should seek additional treatment.

In the two studies the Sensitivity to Endocrine Therapy (SET) Index score predicted distant relapse free survival among 453 patients who received tamoxifen
'/>"/>

Contact: Scott Merville
sdmervil@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Acupuncture provides relief
2. Micro-camera provides new breast imaging technique
3. MicroRNA provides new insight into birth defects
4. Hormone therapy provides no heart benefit
5. Drug Spironolactone Provides Renal And Cardioprotection In Diabetic Patients
6. Neurobiology Provides Answers To Block Memory-Related Drug Cravings
7. Cholesterol provides immunity against infection by certain parasites
8. John Hopkins CGHH program provides Global Health education
9. Protein provides antioxidant protection to Neurons
10. London Hospital Provides Specialized Care For Pregnant Women
11. Study Provides Evidence That Obesity Leads To A More Aggressive Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Approximately a year ago, the leading journal Science ... Alzheimer,s drug. A significant breakthrough and an important starting ... Bart De Strooper Alzheimer,s researcher at VIB and ... Rudi D,Hooge KU Leuven and scientists at ... various Alzheimer,s animal test models. Their results were different, ...
(Date:5/23/2013)... to be tested in a clinical trial by a ... Alzheimer,s disease has failed to work with the same ... to results of a study by University of Florida ... affiliated with the Evelyn F. and William L. McKnight ... importance of verifying promising research results before investing in ...
(Date:5/23/2013)... May 23, 2013 Dr. Katherine Ahn ... charitable organization in Orange County, OCCares , will hold ... County. The event details are as follows: , Sunday ... Auditorium, 13732 Clinton Street, Garden Grove, CA 92843 , The ... music by Christian vocalists Charmaine & Jonathan Thulin. There ...
(Date:5/23/2013)... Fort Myers, FL (PRWEB) May 23, 2013 ... daring prediction in the midst of growing numbers of H7N9 ... of UV-Aid, Predict H7N9 Bird Flu Cases Will Subside in ... of May 13th no new cases have been reported. ... of the flu is as predictable as flowers budding in ...
(Date:5/23/2013)... 23 (HealthDay News) -- Schools should ensure that ... activity each day to support their health and ... report. Although previous studies show 60 ... health and development, it,s estimated that only about ... this recommendation, according to the report from the ...
Breaking Medicine News(10 mins):Health News:New insights contradict promising Alzheimer's research 2Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 2Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 3Health News:Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares 2Health News:Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares 3Health News:UV Technologies Bold Prediction on H7N9 in China Comes True, New Cases End Without Aid of Flu Vaccine 2Health News:UV Technologies Bold Prediction on H7N9 in China Comes True, New Cases End Without Aid of Flu Vaccine 3Health News:U.S. School Kids Should Get Hour of Exercise Daily: Report 2
... with a history of severe milk allergy can safely drink ... research led by the Johns Hopkins Children,s Center and published ... of Allergy and Clinical Immunology . Investigators followed up ... earlier Hopkins Children,s-led study published in 2008 in which patients ...
... , NEW YORK, NY, Aug. 18 /PRNewswire-FirstCall/ - (OTCBB: ... that identifies, acquires, and develops novel drug targets that ... Whiteman as its Chief Executive Officer. , Mr. Whiteman, ... London School of Economics . He will provide ...
... , Miami ... Area , , ... today to participating in a conspiracy to defraud the Medicare program of ... Division, U.S. Attorney Terrence Berg of the Eastern District of Michigan and ...
... , HATBORO, Pa., Aug. 18 ... IFLG ), a leading technology provider of enterprise ... that it has successfully achieved Motorola,s Enterprise Mobility Validation for ... Controller (MDC), InfoLogix,s innovative application platform for mobile ...
... , MOUNT PROSPECT, Ill., Aug. 18 The ... KnujOn for spotlighting the exploitation of search engines, advertising programs ... Prescription Drug Sponsored Search Results," released on August 18, 2009, ... Yahoo!,s online advertising program. , , ...
... , PRINCETON, N.J., Aug. 18 Covance (NYSE: ... with Merck to provide a broad array of genomics analysis services ... Gene Expression Laboratory. Effective August 17, 2009, Covance assumed control ... , About Covance , Covance, with ...
Cached Medicine News:Health News:Milk is safe, even encouraged, for some children after treatment for milk allergy 2Health News:GENova names Aaron Whiteman as CEO 2Health News:GENova names Aaron Whiteman as CEO 3Health News:Detroit Clinic Owner and Patient Recruiter Plead Guilty in $15 Million Fraud Scheme 2Health News:Detroit Clinic Owner and Patient Recruiter Plead Guilty in $15 Million Fraud Scheme 3Health News:Detroit Clinic Owner and Patient Recruiter Plead Guilty in $15 Million Fraud Scheme 4Health News:InfoLogix Achieves Motorola Enterprise Mobility Validation 2Health News:InfoLogix Achieves Motorola Enterprise Mobility Validation 3Health News:NABP Applauds LegitScript and KnujOn for Spotlighting Exploitation of Internet Ad Programs by Rogue Internet Drug Outlets 2Health News:Covance and Merck & Co., Inc. Finalize Strategic Agreement 2
(Date:5/23/2013)... SAN DIEGO , May 23, 2013 /PRNewswire/ ... the prostate cancer treatment continuum was highlighted prominently ... the American Urological Association (AUA), in San Diego.  ... invasive high intensity focused ultrasound (HIFU) technology, the ... localize disease, and for urologists to consider minimally ...
(Date:5/23/2013)... -- Spring Bank Pharmaceuticals, Inc., a biopharmaceutical company developing innovative ... that it has initiated dosing in a Phase I ... therapy for the treatment of HCV infection. This study will ... to assess both the safety and antiviral efficacy of ... the treatment of chronic HCV infections and is based ...
(Date:5/23/2013)... AVIV, Israel , May 23, 2013 ... BrainTech Israel 2013 , Israel,s ... place on October 14 th -15 th in ... nd most innovative city in the world by the ... "Start-up Nation." BrainTech Israel 2013 will showcase the ...
Breaking Medicine Technology:Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 2Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 3Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 4Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 5Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 6Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 2Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 3Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 2Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 3
... in Excess of $10 Million; Access Gains Second ... SEOUL, South Korea, Feb. 19 ... and JCOM Ltd , an ... the Republic of Korea, today announced the signing of ...
... Were Performed on AMI Patients in 2008, According to ... Millennium Research Group,s (MRG,s) US Markets for Interventional ... stents will continue to climb steadily through 2013, driven ... coronary intervention (PCI) in Acute Myocardial Infarction (AMI) patients, ...
Cached Medicine Technology:Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea 2Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea 3Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea 4Adoption of PCI in AMI Patients to Drive Drug-Eluting Stent Use 2
... provides a simple, fast and cost-effective method ... samples. This system utilizes guanidine thiocyanate and ... and denature proteins. Purified viral RNA is ... and RNase protection assays. This system is ...
... The Titertek MAP-C2 is designed for ... the instrument is the S60 Stacker that ... removable magazines. The MAP-C2 base model is ... assembly. Auxiliary Digiflex pipetting units may be ...
Grab one and go, One of the smallest handheld oximeters available, Datex-Ohmeda s TuffSat is the ideal spot-check solution for hospital, home care, transport, and EMS. TuffSat comes fully loaded wi...
The IL 682 is the Gold Standard for CO-Oximetry analysis....
Medicine Products: